VivoSeq
Neurology

Primary Ciliary Dyskinesia

4

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Primary Ciliary Dyskinesia is an early-stage landscape with 4 programs across 4 companies. The most active players are Glaxo Dba Glaxosmithkline, Neurim Pharmaceuticals Ltd., Vertex Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Glaxo Dba Glaxosmithkline

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 2M

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Not yet recruiting1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT04901715·27 enrolled
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
Completed·PParion Sciences·Phase 2·NCT02871778·123 enrolled
Evaluating Non-ciliary Mechanisms of Airway Clearance in Muco-obstructive Lung Disease
Not yet recruiting·UUniversity of North Carolina, Chapel Hill·Preclinical·NCT07699302·8 enrolled
Utility of PCD Diagnostics to Improve Clinical Care
Recruiting·VVanderbilt University Medical Center·Preclinical·NCT03704207·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)